Navigation Links
Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Date:4/18/2008

s are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 18, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
2. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
3. Osteotech to Present at the Sidoti Conference in New York
4. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
7. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
8. Osteotech to Present at Sidoti Conference in San Francisco
9. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , MARKHAM, ON, Nov. 25 /PRNewswire/ - Cyt...oldt, PhD to its Board of Directors. Dr. Moldt wil...tative on the Company,s Board. The number of Board...We are very pleased to welcome Peter Moldt to the ...rience and guidance as Cytochroma continues to mak...
(Date:11/24/2009)..., , HOUSTON, Nov. 24 /PRNewswire-FirstC...rovider of electrical and communications systems a...idential markets, announced today that its commerc...m Manhattan Torcon JV to install the electrical sy...cement facility at the U.S. Army Medical Research ...
(Date:11/24/2009)..., , REYKJAVIK, Iceland, No...s, Inc. (Nasdaq: DCGN ) today announced that it ha...t trading in the company,s common stock will be,su...will be filed with the,Securities and Exchange Com...rom listing on Nasdaq, unless the company files an...
(Date:11/24/2009)..., , SAN MATEO, Calif., Nov. 24 /PRNewsw..., a biopharmaceutical company focused on developin...ies, announced today that Anthony DiTonno, Preside...esent at the 21st Annual Piper Jaffray Health Care...New York Palace Hotel in New York, New York. ,...
Breaking Biology Technology:Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
...b. 7 Genelabs,Technologies, Inc. (Nasdaq: GNLB )...Fred Driscoll will present a company update at the...a Hotel Tuesday, February 12, 2008 at 2:00,pm E.T....e and may be accessed by,going to the Investor Inf...//www.genelabs.com or through the following URL:,...
...bruary 7 Enigma Diagnostics,the life sciences com...s,announces today that it has signed license agree...gned 6 February 2008, include a Real-Time Instrume... License Agreement. These,agreements provide Enigm...,Applera for real-time PCR thermal cyclers and rea...
...Biodel Inc. (Nasdaq:,BIOD) today announced the pri...000 shares of its common stock at a price to the p...d in the offering, 3,260,000 shares are being,issu... sold by certain,stockholders of the Company. Biod...ng of approximately $46.4 million, after deducting...
Other Biology Technology:Genelabs Technologies to Present at the BIO CEO & Investor Conference 2Enigma Signs Real-Time PCR Licences With Applera 2Biodel Inc. Announces Pricing of Public Offering 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wil... report revealing that the last remaining populati...antly due to the rising tide of poaching and habit...help inform Russian officials of what needs to be ...,s biggest cat. , The report was re...
(Date:11/24/2009)... constitutes fish food is a matter of debate. A hi...sh get almost 50 percent of their carbon from tree...en the terrestrial and aquatic ecosystems. , But...ows this is not likely to be true. Algae provide a... according to research published this week in the ...
(Date:11/24/2009)... release is available in Spanish . , The pr... levels of inflammatory substances in the blood, h... shown by a research project of the University of ...cientist at the School of Pharmacy. , The projec... in relation to the control of body weight and inf...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2Fox Chase researchers identify differences in treatments and outcomes of patients with second primary lung cancers versus those with one primary lung 53420 1Fox Chase researchers identify differences in treatments and outcomes of patients with second primary lung cancers versus those with one primary lung 53420 2Leave Worries Behind When Packing for Vacation 53417 1New DrainEx 28TM 29 Catheter Simplifies Insertion and Replacement 53416 1New DrainEx 28TM 29 Catheter Simplifies Insertion and Replacement 53416 2
...cientists and regulators to manage uncertainty and...the Economic and Social Research Council. Efforts ... however, a balancing act where the autonomy of sc...be weighed against the need for comparable data. ...roduction of human embryonic stem cells and move t...
... evolve, biologists have unearthed several interes...l, but the largest members of a taxonomic group --... or the African elephant are often thousands or m...Now for the first time two SFI researchers explain...ework. , "The agreement between our model and rea...
... for food service and salad mixes is an increasing...ttuce is highly perishable, and the cutting requir..., Packaging cut lettuce and other fresh produce i...ia a technique called "modified-atmosphere packagi...ging for lettuce and certain salad greens has led ...
Other Biology News:Standards in stem cell research 2Standards in stem cell research 3Predicting the distribution of creatures great and small 2Good breeding increases shelf life 2
GIBCO CMRL Medium-1066 (1X) liquid from Invitrogen
Rabbit Anti-T-box 6 Monoclonal Antibody, Unconjugated, Clone PADZMD.501 from Invitrogen
Goat Anti-TNF-R2 (L-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
H2A.X Phosphorylation Assay Kit (Flow Cytometry) from Upstate
Biology Products: